Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in China
This study demonstrates that reducing payment barriers has a greater impact on real-world adoption of innovative therapies than clinical efficacy alone. Addressing financial constraints also enhances patients' willingness to pay. These findings provide evidence-based insights for developing patient-centered clinical decision pathways.
Authors
- Arui Tan (ORCID: https://orcid.org/0000-0001-8997-3076)
- Jieying Li (ORCID: https://orcid.org/0000-0002-0576-1891)
- Jun Xiao (ORCID: https://orcid.org/0000-0003-1562-3342)
- Wenqian Feng (ORCID: https://orcid.org/0000-0003-3561-5593)
- Étienne Aumont (ORCID: https://orcid.org/0000-0002-8997-7090)
- Xiaohong Qin (ORCID: https://orcid.org/0000-0002-6100-1088)
- Xiaofeng Li (ORCID: https://orcid.org/0000-0002-6323-7908)
- Yi Yang (ORCID: https://orcid.org/0009-0006-4909-592X)
- Jianwei Yang
- Bo Zhou (ORCID: https://orcid.org/0000-0001-8950-8799)
- Yi Xing (ORCID: https://orcid.org/0000-0003-4931-015X)
- Xiong Yang
- Aonan Li (ORCID: https://orcid.org/0009-0004-9144-0382)
- Zuxing Wang
Institutions
- Fujian Medical University (CN)
- University of Electronic Science and Technology of China (CN)
- Capital Medical University (CN)
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Sichuan Provincial Hospital of Traditional Chinese Medicine (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Alzheimer Disease & Associated Disorders
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1097/wad.0000000000000689
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00